Bajaj Healthcare Limited reported a net profit of ₹13.7 crore for the quarter ended June 30, 2026, an increase of 15.8% compared to the same period last year. The company's revenue from operations grew 11.3% year-on-year to ₹165.63 crore, driven by strong performance in its API division. The improved financial results were supported by an expansion in EBITDA margins to 17.8% from 17.0% in the corresponding quarter of the previous year.

Financial Performance

The company's EBITDA for Q1FY27 stood at ₹29.6 crore, up from ₹25.4 crore in Q1FY26. Gross profit increased 16.2% to ₹80.4 crore, with gross margins expanding to 48.3% from 46.2% in Q1FY26. Profit after tax (PAT) margin improved to 8.3% from 8.0% in the prior year. Sequentially, revenue grew 8.2% from ₹153.06 crore in the preceding quarter, while PAT increased 31.8% from ₹10.40 crore.

Segment Performance

The API division delivered a strong performance during the quarter. Domestic API sales rose 27.1% year-on-year to ₹92.26 crore, driven by volume growth across key products. API export sales were ₹50.06 crore, compared to ₹52.19 crore in Q1FY26, impacted by temporary disruptions from the geopolitical situation in West Asia. Formulations revenue was ₹23.31 crore, a marginal decline from ₹24.05 crore in the previous year, which the company expects to normalize as the financial year progresses.

Business Updates

Bajaj Healthcare secured a recommendation from the US Securities and Exchange Commission (SEC) for the manufacture and marketing of Cenobamate Tablets, a milestone towards commercializing this anti-seizure medication. The company filed two CEP applications during the quarter, bringing cumulative filings to twelve, with eight approved and four under review to strengthen its presence in the EU and UK markets. The company's expanded R&D Centre at Savli has become operational.

Regulatory Disclosure

In an intimation under Regulation 30 of SEBI (LODR) Regulations, 2015, the company confirmed that the audio recording of the earnings call held on July 21, 2026, to discuss the financial performance for the quarter ended June 30, 2026, has been uploaded to its website.

Bajaj Healthcare Limited granted 275 stock options to an eligible employee under its Bajaj Healthcare Limited Employee Stock Option Plan 2024. The Nomination & Remuneration Committee approved the grant at an exercise price of ₹5 per option on July 20, 2026. Each option is convertible into one fully paid-up equity share with a face value of ₹5, covering a total of 275 equity shares.

The scheme is in terms of the SEBI (SBEB) Regulations, 2021. Options vest over a maximum period of four years from the date of grant, with a minimum period of one year between the grant and vesting. Vested options may be exercised by the grantee within five years from the date of vesting.

Grant Details

Eligibility for participation includes employees working in India or abroad, and directors who are not promoters or independent directors. The scheme excludes employees who are promoters or belong to the promoter group, as well as independent directors. Shares arising from the exercise of options are not subject to a lock-in period, though trading restrictions under the company's insider trading code apply.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.